U.S. markets open in 57 minutes
  • S&P Futures

    4,138.75
    +14.25 (+0.35%)
     
  • Dow Futures

    32,826.00
    +89.00 (+0.27%)
     
  • Nasdaq Futures

    13,089.25
    +57.75 (+0.44%)
     
  • Russell 2000 Futures

    1,919.80
    +5.20 (+0.27%)
     
  • Crude Oil

    89.26
    -1.24 (-1.37%)
     
  • Gold

    1,807.00
    -5.30 (-0.29%)
     
  • Silver

    20.40
    -0.09 (-0.42%)
     
  • EUR/USD

    1.0319
    +0.0101 (+0.99%)
     
  • 10-Yr Bond

    2.7970
    0.0000 (0.00%)
     
  • Vix

    22.16
    +0.87 (+4.09%)
     
  • GBP/USD

    1.2216
    +0.0140 (+1.16%)
     
  • USD/JPY

    133.0260
    -2.0900 (-1.55%)
     
  • BTC-USD

    23,104.24
    -192.89 (-0.83%)
     
  • CMC Crypto 200

    538.26
    -19.09 (-3.43%)
     
  • FTSE 100

    7,490.09
    +1.94 (+0.03%)
     
  • Nikkei 225

    27,819.33
    -180.63 (-0.65%)
     

Novavax enters deal with New Zealand for 10.7M doses of COVID-19 vaccine candidate

  • Oops!
    Something went wrong.
    Please try again later.
Novavax enters deal with New Zealand for 10.7M doses of COVID-19 vaccine candidate
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

Dec 17 (Reuters) - Biotechnology company Novavax Inc said it had entered an agreement with the government of New Zealand for 10.7 million doses of its COVID-19 vaccine candidate.

"Under the terms of the agreement, Novavax will manufacture NVX-CoV2373 with a target of delivering initial doses by mid-2021", it said in a statement on Thursday.

The company will work with New Zealand's regulatory agency, Medsafe for approvals, it added.

The statement did not disclose further terms of the agreement. (Reporting by Kanishka Singh in Bengaluru; Editing by Himani Sarkar)